Too good to be brew! DMT - the potent psychedelic in Ayahuasca - treats depression after a SINGLE dose, cutting-edge clinical trial shows - Thelocalreport.in

Too good to be brew! DMT – the potent psychedelic in Ayahuasca – treats depression after a SINGLE dose, cutting-edge clinical trial shows

DMT – the most potent psychedelic known to man – treats people with severe depression after a single dose, a cutting-edge clinical trial suggests.

– Advertisement –

Six out of ten people who received a single dose of DMT before treatment were declared depression-free after three months.

advertisement

And three out of 10 participants were declared depression-free two weeks after one session, compared to one out of ten in the placebo group who only had therapy on its own.

N,N-Dymethyltryptamine (DMT) has been endorsed by celebrities like Joe Rogan and is growing in popularity as an alternative to harsher antidepressants. Recently, Prince Harry admitted to using ayahuasca to help heal the trauma he felt after his mother’s death.

– Advertisement –

DMT is the natural psychedelic in ayahuasca, widely used by tribal societies in the Amazon basin, where it is considered a ‘wisdom’ plant that allows entry into the spiritual world.

Ayahuasca is commonly drunk as a decoction in religious ceremonies, but in this study, participants received DMT via an IV drip for 10 minutes, which induced a 20–30-minute psychedelic experience.

These graphs show the percentage of responders after one week and two weeks of dosing, as measured by a decrease of greater than or equal to 50 percent in Madras from baseline on the left hand side.  For the group receiving DMT, the remission rate was 44 percent after one week and 35 percent after two weeks.  The response rates were six percent and 12 percent in the placebo group.  The graph on the right shows the remission rates determined by MADRS scores of less than or equal to 10 at one week and two weeks.  Remission rates at one week and two weeks were 44 percent and 29 percent for the DMT treatment group, while placebo remission rates were 13 percent and 12 percent.  Data show clinically relevant changes in response and remission rates after DMT treatment

These graphs show the percentage of responders after one week and two weeks of dosing, as measured by a decrease of greater than or equal to 50 percent in Madras from baseline on the left hand side. For the group receiving DMT, the remission rate was 44 percent after one week and 35 percent after two weeks. The response rates were six percent and 12 percent in the placebo group. The graph on the right shows the remission rates determined by MADRS scores of less than or equal to 10 at one week and two weeks. Remission rates at one week and two weeks were 44 percent and 29 percent for the DMT treatment group, while placebo remission rates were 13 percent and 12 percent. Data show clinically relevant changes in response and remission rates after DMT treatment

DMT and ayahuasca are part of a wave of psychedelics, along with psilocybin mushrooms and ketamine, that were dismissed as hippie drugs but are now being explored by scientists as powerful therapeutics.

The latest study was done in 2021 by Small Pharma, a Canada-based biotech company.

It looked at 34 male and female participants with moderate or severe depression.

In the first part of the trial, 17 participants received 21.5mg of DMT, roughly half the usual smoked dose.

He received the drug through an IV drip for 10 minutes, which induced a 20–30-minute psychedelic experience, immediately followed by a therapy session to help him make sense of it.

The other 17 patients received therapy only.

Independent reviewers, who did not know what treatment the participants were receiving, assessed people’s depression using the Montgomery-Asberg Depression Rating Scale (MADRS) at the start of the trial and again after one, two and 12 weeks.

One week after dosing, the DMT group showed a minus 10.8 change in MADRS scores versus the placebo group.  After two weeks, there was a minus 7.4 difference in depression scores in the group receiving DMT compared to the placebo group.

One week after dosing, the DMT group showed a minus 10.8 change in MADRS scores versus the placebo group. After two weeks, there was a minus 7.4 difference in depression scores in the group receiving DMT compared to the placebo group.

Researchers Create Ayahuasca Pill

A medical-grade version of the popular hippie brew ayahuasca could be available to Americans within the next decade.

Two weeks after treatment, the DMT group’s depression score was 7.4 points lower than the placebo group, indicating a statistically significant reduction in depressive symptoms compared to placebo.

And three months after receiving the treatment, symptoms were reduced even further – the overall average reduction in MADRS score after a single dose of DMT was 15.4 points.

Six out of ten of those who took a single dose of DMT were also declared depression-free after three months.

This was defined as a MADRS score of ten or less.

Dr David Aritzou, clinical psychiatrist at Imperial College London and principal investigator of the study, said: ‘The results are exciting for the field of psychiatry. We now have the first evidence that DMT, combined with supportive therapy, can be effective for people with MDD.

‘For patients unfortunate enough to experience little benefit from existing antidepressants, the prospect of rapid and durable relief from a treatment, as shown in this trial, is very promising.’

So far, the medical benefits of DMT have been mainly anecdotal, with evidence showing that the drug also carries a risk of long-lasting negative effects on mental health.

Scientific details on what exactly DMT does to the brain are scant, but research suggests that it increases the ‘use rate’ of monoamines within the amygdala, which increases the intensity of memories.

There is also increased blood flow to the insula, which may account for users’ increased sense of self.

This is believed to make therapy more effective, as people can face their trauma with less fear.

Leave a Comment

x